Wesana Health Holdings Inc. (WSNAF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Wesana Health Holdings Inc. (WSNAF) trades at $0.0035. Wesana Health Holdings Inc. is a life sciences company focused on developing psychedelic medicines and therapies for traumatic brain injuries. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for WSNAF: WSNAF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates WSNAF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
WSNAF: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Wesana Health Holdings Inc. (WSNAF) Healthcare & Pipeline Overview
Wesana Health Holdings Inc. develops psychedelic medicines and psilocybin-assisted psychotherapies targeting traumatic brain injuries, positioning itself within the emerging biotechnology sector focused on mental health treatments. The company is based in Chicago and operates with a small team, emphasizing evidence-based formulations and protocols.
What Is the Investment Thesis for WSNAF?
Wesana Health Holdings Inc. presents a high-risk, high-reward investment opportunity within the emerging psychedelic medicine sector. The company's focus on traumatic brain injuries provides a specific niche, but the small market capitalization of $0.00B and negative P/E ratio of -0.33 indicate significant financial challenges. Key value drivers include successful clinical trials and regulatory approvals for its psilocybin-assisted therapies. Growth catalysts involve partnerships with research institutions and expansion of treatment protocols. However, the company's OTC listing and limited financial disclosure pose substantial risks. Investors should closely monitor clinical trial outcomes, regulatory developments, and the company's ability to secure funding to sustain operations.
Based on FMP financials and quantitative analysis
WSNAF Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with high growth potential but also significant risk.
- P/E ratio of -0.33 reflects the company's current lack of profitability, typical for early-stage biotechnology firms.
- Beta of -0.76 suggests a negative correlation with the market, potentially offering some downside protection during market downturns, but also indicating limited upside capture.
- Focus on psychedelic medicines and psilocybin-assisted psychotherapies positions the company in a high-growth, albeit highly regulated, segment of the healthcare industry.
- Based in Chicago, Illinois, providing access to a strong talent pool and research infrastructure.
Who Are WSNAF's Competitors?
WSNAF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are WSNAF's Key Strengths?
Specialized focus on traumatic brain injuries.
- Development of psychedelic medicines and therapies.
- Potential for patent protection.
- Innovative approach to mental health treatment.
What Are WSNAF's Weaknesses?
Limited financial resources.
- Small team and operational scale.
- Dependence on regulatory approvals.
- Early stage of development.
What Could Drive WSNAF Stock Higher?
Publication of results from ongoing clinical trials of psilocybin-assisted therapies.
- Potential partnerships with research institutions to expand research capabilities.
- Regulatory milestones, such as FDA approvals for novel therapies.
- Increasing awareness and acceptance of psychedelic medicines for mental health treatment.
- Expansion of the company's intellectual property portfolio through patent filings.
What Are the Key Risks for WSNAF?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles and changing regulations regarding psychedelic medicines.
- Competition from established pharmaceutical companies with greater resources.
- Negative public perception of psychedelic medicines and potential side effects.
- Limited financial resources and dependence on external funding.
- Uncertainty surrounding clinical trial outcomes and efficacy of therapies.
What Are the Growth Opportunities for WSNAF?
- Expansion of Clinical Trials: Wesana Health has the opportunity to expand its clinical trials to include a broader range of patients with traumatic brain injuries (TBIs). By demonstrating the efficacy and safety of its psilocybin-assisted therapies in larger, more diverse populations, Wesana can strengthen its position in the market and attract further investment. The global market for TBI treatment is estimated to reach $4.2 billion by 2027, providing a substantial opportunity for Wesana to capture market share through successful clinical trials.
- Strategic Partnerships with Research Institutions: Collaborating with leading research institutions and universities can accelerate Wesana's research and development efforts. By partnering with experts in neurology, psychology, and psychedelic medicine, Wesana can gain access to cutting-edge research, advanced technologies, and a network of potential collaborators. These partnerships can enhance the credibility of Wesana's therapies and facilitate the development of innovative treatment protocols. The timeline for establishing these partnerships is ongoing, with potential benefits realized within the next 1-3 years.
- Regulatory Approvals and Market Access: Securing regulatory approvals from agencies such as the FDA is crucial for Wesana's long-term success. Obtaining approval for its psilocybin-assisted therapies would allow Wesana to market and sell its products to a wider audience, including healthcare providers and patients. The regulatory pathway for psychedelic medicines is evolving, and Wesana must navigate this complex landscape effectively to gain market access. The timeline for regulatory approvals is uncertain but could potentially occur within the next 3-5 years.
- Development of Proprietary Formulations: Wesana Health can focus on developing proprietary formulations of psilocybin and other psychedelic compounds to differentiate itself from competitors. By creating unique formulations with enhanced bioavailability, targeted delivery, or improved therapeutic effects, Wesana can gain a competitive advantage in the market. The development of proprietary formulations requires ongoing research and development efforts, with potential breakthroughs occurring within the next 2-4 years.
- Expansion into Adjacent Therapeutic Areas: While Wesana's initial focus is on traumatic brain injuries, the company can explore opportunities to expand its therapies into adjacent therapeutic areas, such as post-traumatic stress disorder (PTSD), depression, and anxiety. These conditions often co-occur with TBIs, and Wesana's therapies may have potential benefits for these patients as well. The market for mental health treatments is substantial, with the global market for antidepressants alone projected to reach $15.8 billion by 2027. This expansion could occur within the next 3-5 years, pending successful clinical trials and regulatory approvals.
What Are WSNAF's Competitive Advantages?
- Proprietary formulations of psychedelic medicines.
- Specialized focus on traumatic brain injuries.
- Expertise in psilocybin-assisted psychotherapy.
- Potential for patent protection on novel therapies.
What Does WSNAF Do?
Wesana Health Holdings Inc. is a life sciences company dedicated to the development and delivery of psychedelic medicines and psilocybin-assisted psychotherapies for treating traumatic brain injuries (TBIs). Founded with the vision of addressing neurological, psychological, and mental health ailments caused by trauma, the company is headquartered in Chicago, Illinois. Wesana is focused on creating evidence-based formulations and treatment protocols designed to empower patients in their recovery journey. The company's core focus is on leveraging the potential of psychedelic compounds, particularly psilocybin, in therapeutic settings. Wesana is involved in researching and developing proprietary formulations and treatment methodologies that utilize psilocybin-assisted psychotherapy to treat the symptoms and underlying causes of TBIs. The company aims to provide innovative solutions for individuals suffering from the long-term effects of brain trauma, including cognitive impairment, emotional dysregulation, and mental health disorders. Wesana Health operates within the rapidly evolving biotechnology sector, specifically targeting the intersection of psychedelic medicine and mental health. The company's approach involves a combination of pharmaceutical development and therapeutic practices, seeking to create comprehensive treatment programs that address both the physical and psychological aspects of TBIs. With a small team of 7 employees, Wesana is focused on advancing its research and development efforts, navigating the regulatory landscape, and establishing partnerships to expand its reach and impact in the field of psychedelic medicine.
What Products and Services Does WSNAF Offer?
- Develop psychedelic medicines for treating traumatic brain injuries.
- Research and create psilocybin-assisted psychotherapy protocols.
- Focus on evidence-based formulations for neurological ailments.
- Target psychological and mental health issues caused by trauma.
- Offer innovative solutions for cognitive impairment.
- Address emotional dysregulation related to brain injuries.
- Aim to improve the long-term effects of brain trauma.
How Does WSNAF Make Money?
- Develop and patent proprietary psychedelic drug formulations.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approvals for market access.
- Partner with clinics and healthcare providers for treatment delivery.
What Industry Does WSNAF Operate In?
Wesana Health operates within the biotechnology industry, specifically targeting the emerging field of psychedelic medicine. The market for psychedelic-assisted therapies is projected to grow significantly, driven by increasing acceptance of these treatments for mental health disorders and neurological conditions. The competitive landscape includes companies like AREV (Adamas One Corp.), CHNXF (ChampionX Corporation), GRVE (Grove Collaborative Holdings, Inc.), IPIX (Ipix Corp), and LFCOF (Lifeist Wellness Inc.), which are exploring various approaches to mental health treatment. Wesana's focus on traumatic brain injuries differentiates it within this competitive environment, but the company faces challenges related to regulatory approvals, clinical trial outcomes, and market adoption.
Who Are WSNAF's Key Customers?
- Individuals suffering from traumatic brain injuries.
- Patients with neurological and psychological ailments.
- Healthcare providers seeking innovative treatment options.
- Research institutions and universities.
Forward Outlook
Wall Street analysts project Wesana Health Holdings Inc. revenue of about $278K for fiscal 2026, with EPS near $-0.89.
Financial Health
Wesana Health Holdings Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Company Profile
Wesana Health Holdings Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Chicago, US. The company is led by CEO Daniel Carcillo. WSNAF has traded publicly since 2021.
WSNAF Financials
Bull Case vs Bear Case
Bull Case
- Specialized focus on traumatic brain injuries.
- Development of psychedelic medicines and therapies.
- Potential for patent protection.
- Innovative approach to mental health treatment.
Bear Case
- Limited financial resources.
- Small team and operational scale.
- Dependence on regulatory approvals.
- Early stage of development.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
WSNAF Latest News
No recent news available for WSNAF.
WSNAF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for WSNAF.
Price Targets
Wall Street price target analysis for WSNAF.
WSNAF MoonshotScore
What does this score mean?
The MoonshotScore rates WSNAF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Daniel Carcillo
CEO
Daniel Carcillo is the CEO of Wesana Health Holdings Inc. His background includes experience in professional sports, providing him with insights into the impact of traumatic brain injuries. He leverages this personal understanding to drive the company's mission of developing effective treatments for TBIs. Carcillo's leadership focuses on advancing research, securing partnerships, and navigating the regulatory landscape to bring innovative therapies to patients in need.
Track Record: Under Daniel Carcillo's leadership, Wesana Health has focused on developing psilocybin-assisted therapies for traumatic brain injuries. Key milestones include initiating clinical trials and establishing partnerships with research institutions. Carcillo's strategic decisions have centered on advancing the company's research pipeline and securing funding to support its operations. He manages a team of 7 employees.
WSNAF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Wesana Health Holdings Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide regular financial reporting, increasing the risk for investors. Trading on the OTC Other tier is distinct from trading on major exchanges like the NYSE or NASDAQ, which have stricter listing standards and reporting requirements.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Low trading volume and liquidity can lead to price volatility.
- Higher risk of fraud or manipulation compared to listed exchanges.
- OTC Other companies often have limited operating history or financial stability.
- Regulatory oversight is less stringent than on major exchanges.
- Verify the company's registration and legal standing.
- Attempt to locate and review any available financial statements.
- Assess the company's management team and their experience.
- Understand the company's business model and competitive landscape.
- Evaluate the potential market for the company's products or services.
- Consult with a financial advisor before investing.
- Be aware of the risks associated with OTC investing.
- Focus on a specific niche within the healthcare sector (traumatic brain injuries).
- Development of psychedelic medicines and therapies.
- CEO with relevant experience and a clear mission.
- Company based in Chicago, a major metropolitan area.
- Presence of a website and investor relations materials (if available).
What Investors Ask About Wesana Health Holdings Inc. (WSNAF) — Healthcare
What does Wesana Health Holdings Inc. do?
Wesana Health Holdings Inc. is a life sciences company focused on developing psychedelic medicines and psilocybin-assisted psychotherapies for the treatment of traumatic brain injuries (TBIs). The company aims to address the neurological, psychological, and mental health ailments caused by trauma by creating evidence-based formulations and treatment protocols.
What do analysts say about WSNAF stock?
As of March 17, 2026, there is no readily available analyst coverage for WSNAF stock due to its OTC listing and small market capitalization. Key valuation metrics such as revenue projections and earnings estimates are not widely published.
What are the main risks for WSNAF?
The main risks for Wesana Health Holdings Inc. include regulatory hurdles associated with psychedelic medicines, competition from larger pharmaceutical companies, and the inherent uncertainty of clinical trial outcomes. The company's limited financial resources and dependence on external funding also pose significant risks. Negative public perception of psychedelic medicines and potential side effects could impact market adoption.
What are the key factors to evaluate for WSNAF?
Evaluate WSNAF on fundamentals, analyst consensus, and risk factors. Wesana Health Holdings Inc. presents a high-risk, high-reward investment opportunity within the emerging psychedelic medicine sector. Not financial advice.
How frequently does WSNAF data refresh on this page?
WSNAF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven WSNAF's recent stock price performance?
Wesana Health Holdings Inc. (WSNAF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on traumatic brain injuries. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider WSNAF overvalued or undervalued right now?
Wesana Health Holdings Inc. (WSNAF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research WSNAF before investing?
Before investing in Wesana Health Holdings Inc. (WSNAF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited available data.
- OTC market investments are inherently risky.
- AI analysis is pending and may provide further insights.